Delivering pediatric oncology services during a COVID-19 pandemic in India

To the Editor:

The global pandemic of the novel coronavirus disease, COVID-19, is having a serious impact on pediatric patients, making it difficult for them to continue treatment.1,2

Providing medical care to children with cancer is challenging during the COVID-19 pandemic, given the risks of death from cancer versus death or serious complications from COVID-19 infection in immunocompromised hosts.3-8 There is shortage of personal protective equipment (PPE) for health personnel, restricted inpatient and intensive care facilities, and limited blood bank supplies and diagnostic services.4

In this correspondence, we describe the strategy used in our unit to deliver optimum oncology services during COVID-19 pandemic best suited to our system.

In the initial phases of the COVID-19 pandemic, the main focus was on staying at home, hand/respiratory hygiene, and social distancing. The patients were asked to stay indoors and continue oral chemotherapy wherever feasible and defer the intensive chemotherapy, which would require hospital visits and possible subsequent admission for febrile neutropenia.2,5

Preventive measures during hospital visits: Strict implementation of protective measures, including mask use by patients and their caregivers, hand hygiene, appropriate respiratory etiquette, and social distancing, was enforced. Health education regarding the pandemic was imparted to patients by telephone and during day care visits. Patients with suspected COVID-19 were screened. Testing/quarantine/admission was advised on a case-by-case basis. The protocol followed in the unit for evaluation of patients with febrile neutropenia was modified: throat examination and aerosol generating procedures were withdrawn. Children may act as asymptomatic carriers leading to community spread. Strict crowd control for patients’ attendants was implemented. The hospital had temporarily withdrawn outpatient and specialty clinic services, hence new patients were not registered. Patients presenting with oncologic emergencies and those requiring high-dose chemotherapy were admitted. Those requiring inpatient admissions for intensive chemotherapy adhered to a strict appointment system.

The lockdown: By the third week of COVID-19 pandemic, a nationwide lockdown had been declared. We set a system of triage for our patients that helped the oncology team to make decisions for our patients (Table 1).

Patient tracking/teleconsultations was done by our nurses and social workers, and assisted by the doctors (Table 1).

Revisiting the treatment plan: Triage was done for patients on chemotherapy. Patients were allocated to a risk zone and relevant treatment advice was given. Treatment protocols requiring surgery/radiation/hematopoietic stem cell transplantation needed modification, as these therapeutic modalities were temporarily suspended due to COVID-19 concerns. Occasionally, patients were switched to low-dose/less toxic chemotherapy to tide over this critical period (Table 1).

Reorganization of day care services was done to facilitate treatment (Table 2).

Resource utilization: Ours is a premier tertiary medical institute in India and has been designated a COVID-19 center. Understanding the nature of the COVID-19 disease and requirements of the pandemic, the team of doctors and nurses was split into two. This splitting of resources keeps a reserve pool of medical staff, should one team inadvertently be exposed to a COVID-19 case.

Role of telehealth: Patients were contacted and helped by telephone, helplines, and emails and using a support group called “Sambhav.” More than 170 exchanges were done.

NGO interface: Our NGO partners helped with antibiotic administration, transport within the city and across states, accommodation, and coordination with local hospitals. They also helped transfer medicines to distant patients.

Blood donation: The lockdown had drastically reduced the number of voluntary blood donations and donations from relatives, resulting in a shortage of blood components in the blood bank. Travel documents were issued by the treating team to permit donors to come for voluntary blood donation.

The pandemic caused by SARS-CoV-2 (COVID-19) has greatly affected the delivery of care for children with cancer worldwide. Information on COVID 19 infection in pediatric cancer patients is scarce.9 In our unit, we conducted COVID-19 testing for seven patients, of which one tested positive. All patients were febrile, had cough and tachypnoea (of these two were hypoxic), shock was present in two, and pneumothorax was present in one patient. One patient came from a hotspot area. The one patient who was COVID-19 positive in addition had features of meningoencephalitis.

A number of studies from around the world5,8,10,11 have suggested dose reductions, increasing intervals between cycles depending on the physical status of patient, disease status, and risk of chemotherapy. It seems desirable to postpone high-intensity treatments where feasible and to prepare to triage according to prognosis.5,8,10 A recent
## TABLE 1  Triage system during COVID-19 pandemic

| Zones and risk     | Patient category                                                                 | Plan                                                                                   |
|-------------------|----------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| Green             | Patients who completed treatment recently                                        | Patients were asked to stay at home. The focus was on adhering to hand/respiratory hygiene and social distancing. Teleconsultation was continued. |
| Very low risk     | Awaiting end treatment assessment/review of reports                                |                                                                                        |
|                   | Long-term survivors                                                               |                                                                                        |
| Blue              | Patients on follow up and not on intensive chemotherapy cycles like ALL maintenance, RB intraocular disease/HL/LCH/RMS mid-treatment showing good response | No need to travel from home town to Delhi. ALL patients may continue maintenance and send CBC/LFT via email. Chemotherapy including ITM may be given at a nearby hospital equipped to give chemotherapy after contacting primary treating team. Chemotherapy for RB/HL/LCH/RMS may be given as prescribed. If not possible, it may be delayed by a few (2-3) weeks. CML patients must continue taking imatinib. |
| Low risk          |                                                                                        |                                                                                        |
| Orange            | Patients requiring surgery/radiation/HSCT                                          | Deferred as elective surgery/radiation had been postponed. Support staff and facility of admission affected hence transplants also postponed. Patients switched to alternative/oral metronomic chemotherapy to bridge the gap. Done by telephonewith respective departments with limitations. |
| Intermediate risk | Interdepartmental consultation (multimodal management)                              |                                                                                        |
| Red               | Delay in chemotherapy is likely to affect outcome (usually high-dose chemotherapy) | Chemotherapy was administered via inhouse admission/day care facility.                  |
| High risk         | Leukemia (induction/consolidation/interim maintenance)                             |                                                                                        |
|                   | Non-Hodgkin lymphoma                                                              |                                                                                        |
|                   | Initial cycles of solid tumors (Ewing sarcoma, RMS, hepatoblastoma, germ cell tumor) |                                                                                        |
| Yellow            | Patients with poor outcome (relapsed and progressive disease on chemotherapy, metastatic tumors with poor survival outcomes) | Counseling with advice on palliation was given and metronomic chemotherapy used wherever applicable. |
| Risk not applicable |                                                                                   |                                                                                        |

Abbreviations: ALL, acute lymphoblastic leukemia; CBC, complete blood count; CML, chronic myeloid leukemia; EUA, examination under anesthesia; HSCT, hematopoietic stem cell transplant; ITM, intrathecal methotrexate; LCH, Langerhans cell histiocytosis; LFT, liver function test; RB, retinoblastoma; RMS, rhabdomyosarcoma.

## TABLE 2  Day care services

| Infection control                                                                 | Screening before entry for possible symptoms/residing in hotspot area |
|----------------------------------------------------------------------------------|-----------------------------------------------------------------------|
|                                                                                  | Testing for COVID-19 infection on decision of treating team           |
|                                                                                  | Compulsory use of mask by child and caregiver                        |
|                                                                                  | Staggering appointment for chemotherapy/procedures                   |
| Social distancing                                                                | Distance of about 6 feet in between patients inside and waiting area outside day care |
|                                                                                  | Limited number of patients were admitted into day care (five at one time) |
|                                                                                  | Chemotherapy (intravenous pushes and intramuscular/subcutaneous injections) given later during the day when the day care is less crowded |
| Telehealth                                                                        | Teleconsultation via phone                                           |
|                                                                                  | Appointments for chemotherapy/procedures given via phone             |
| Change in unit policy to manage febrile neutropenia patients                     | Patients were encouraged to take antimicrobials near their place of stay and avoid hospital visits |
|                                                                                  | Early switch to oral antimicrobials if the clinical condition of the child permitted on a case-to-case basis |
|                                                                                  | Teletracking of affected patients                                    |
|                                                                                  | The evaluation protocol for febrile neutropenia patients was modified: detailed throat examination or aerosol generating interventions were deferred wherever possible or undertaken using PPE |
| Blood component therapy                                                          | Appointment system followed for planned transfusions                 |

Any child presenting with febrile neutropenia and respiratory systems was directed to the pediatric emergency where they went through a complete evaluation for need of testing for COVID-19 and admission as the pediatric emergency was a designated COVID-19 screening area with complete infrastructure for COVID-19 testing.
publication has focused on providing guiding principles for management of various childhood cancers, in particular the ones with best clinical outcomes (acute lymphoblastic leukemia, Hodgkin lymphoma, retinoblastoma, Wilms tumor, and low-grade glioma).12

A balance needs to be created keeping in mind risks associated with COVID-19 and the timely management of a child with cancer.12 At the onset of the pandemic and lockdown where the focus was on social distancing, staying at home, and using a triage system to deliver oncology services, it was realized that this cannot go on indiscriminately. We are now tracking all our patients who received chemotherapy in the last 3 years and facilitating delivery of all pending chemotherapy that was postponed during the initial phases of the pandemic.

ACKNOWLEDGMENTS
We acknowledge the support provided to all the children with cancer by AIIMS (the entire medical staff and administration who facilitated care of our affected children) and CANKIDS-KIDSCAN (our NGO partner).

ETHICAL STATEMENT
This is to certify that there are no ethical issues related to this paper and no human subject data are involved. Therefore, no patient consent was required either.

Rachna Seth
Gargi Das
Kanwaljeet Kaur
R. Mohanaraj
Prasanth Siri
M. Abdul Wajid
Piali Mandal
Debasish Sahoo
Tincy Thomas
Meenakshi Raina
Aditya K. Gupta
Jagdish P. Meena

Pediatric Oncology Division, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India

Correspondence
Rachna Seth, Pediatric Oncology Division, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi 110029, India.
Email: drrachnaseth1967@gmail.com

ORCID
Rachna Seth https://orcid.org/0000-0002-0967-789X
Aditya K. Gupta https://orcid.org/0000-0002-3730-8944

REFERENCES
1. Dong Y, Mo X, Hu Y, et al. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. *Pediatrics*. 2020;145(6):e20200702.
2. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med*. 2020;382:727-733.
3. Yang C, Li C, Wang S. Clinical strategies for treating pediatric cancer during the outbreak of 2019 novel coronavirus infection. *Pediatr Blood Cancer*. 2020;67(5):e28248.
4. Yadav U, Pal R. Challenging times for children with transfusion-dependent thalassemia amid the COVID-19 pandemic. *Indian Pediatr*. 2020;57(5).
5. Pramesh CS, Badwe RA. Cancer management in India during COVID-19. *N Engl J Med*. 2020;382:e61.
6. Kotecha RS. Challenges posed by COVID-19 to children with cancer. *Lancet Oncol*. 2020;21(5):e235.
7. Seth R. COVID-19 pandemic: the challenges for pediatric oncology [published online ahead of print May 4, 2020]. *Indian Pediatr*. 2020. https://www.indianpediatrics.net/COVID29.03.2020/CORR-00171.pdf
8. Bouffet E, Challinor J, Sullivan M, Biondi A, Rodriguez-Galindo C, Pritchard-Jones K. Early advice on managing children with cancer during the COVID-19 pandemic and a call for sharing experiences. *Pediatr Blood Cancer*. 2020;67(7):e28327.
9. Chen Z, Xiong H, Li JX, et al. COVID-19 with post-chemotherapy agranulocytosis in childhood acute leukemia: a case report. *Zhonghua xue ye xue za zhi = Zhonghua xue ye xue za zhi*. 2020;41:E004.
10. Schrag D, Hershman DL, Basch E. Oncology practice during the COVID-19 pandemic. *JAMA*. 2020;323(20):2005-2006.
11. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Oncol*. 2020;21(3):335-337.
12. Sullivan M, Bouffet E, Rodriguez-Galindo C, et al. The COVID-19 pandemic: a rapid global response for children with cancer from SIOP, COG, SIOP-E, SIOP-PODC, IPSO, PROS, CCI, and St Jude Global. *Pediatr Blood Cancer*. 2020;67(7):e28409.